MICU Treatment Protocol

**Amiodarone (Cordarone)**

**Indicators:** Sustained severe ventricular tachycardia, supraventricular tachycardia, atrial fibrillations, ventricular fibrillation not controlled by first-line agents.

**Contra-indications:** Second or third degree AV block, bradycardia.

**Adverse Effects:** Flushing, edema, sinus arrest, hypotension, bradycardia, CHF, dysrhythmias, SA node dysfunction, nausea and vomiting, headache, dizziness, tremors, abdominal pain.

**Administration:** IV bolus 150 mg over 10 minutes (15 mg/min), then 360 mg over 6 hours (1 mg/min), then 540 mg over the remaining 18 hours (0.5 mg/min).

**MICU Directives:**

1. Follow generalized protocol for MICU transports.
2. Maintain drip per sending facility orders.
3. Discontinue if significant adverse effects occur.

<table>
<thead>
<tr>
<th>MCA Approved</th>
<th>05/01</th>
<th>07/02</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implement</td>
<td>05/01</td>
<td>01/03</td>
</tr>
</tbody>
</table>